Other Professional Equipment and Supplies Merchant Wholesalers (U.S., NAICS 42349)

1. Overview

This is the wholesale-distribution layer between the factories that build professional equipment and the specialists who use it — the middlemen who stock, ship, and support laboratory instruments, scientific and analytical gear, veterinary supplies, surveying and geospatial tools, drafting and architects' equipment, classroom supplies, and similar "professional" goods. These firms are merchant wholesalers: they buy products, take ownership and inventory risk, and resell them, mostly business-to-business, to labs, universities, hospitals' research arms, pharmaceutical and biotechnology companies, veterinary clinics, engineering and surveying firms, schools, and government agencies.[1]

NAICS (North American Industry Classification System) code 42349 is a NAICS industry (five-digit level) in U.S. Wholesale Trade. It is a single-child pass-through: it contains exactly one national industry, 423490 — Other Professional Equipment and Supplies Merchant Wholesalers (six-digit level), and is economically identical to it. The five-digit and six-digit codes cover the same firms, the same sales, and the same employment.

Why an investor cares: distribution is a "picks-and-shovels" way to get exposure to research and testing activity without betting on any single instrument brand or scientific outcome, and the consumable half of the business is highly recurring. The catch is that public pure-plays are scarce — the sector is dominated by two national broad-line lab distributors (one of them embedded in a much larger life-sciences company) plus thousands of small private firms, with much of the middle taken private by private-equity buyers.

This page is a short rollup. For full detail on economics, the investable universe, and the outlook, read the child primer, 423490.

2. What's inside — and why the level equals its one child

Under the NAICS hierarchy, industry group 4234 (Professional and Commercial Equipment and Supplies Merchant Wholesalers) splits into several NAICS industries — computers (42343), medical/dental (42345), ophthalmic goods (42346), and this catch-all, 42349. At the five-digit level, 42349 has only one national (six-digit) industry beneath it, 423490. When a NAICS industry has a single child, the two are definitionally the same population, so every figure on this page is also the figure for 423490.[1][2]

What that one child covers, at a glance:[1][2]

• Scientific and laboratory instruments and supplies — analytical instruments (chromatographs, spectrographs, photometers), balances and scales, glassware, reagents and consumables (the largest, most visible slice).
• Veterinary equipment and supplies.
• Surveying and geospatial equipment; drafting and architects'/engineers' equipment.
• School equipment and supplies (except books and furniture).
• Church and religious supplies; wall maps, smartboards, and non-computer teaching machines.

The operative word is merchant: these firms buy on their own account, hold inventory, and extend customer credit. The code excludes medical/dental/hospital equipment (NAICS 423450), ophthalmic goods (423460), computers and office and photographic equipment (423430/423420/423410), drugs and druggists' sundries including most veterinary pharmaceuticals (424210), books and periodicals (424920), school furniture (423210), silverware and plated flatware (423940), and agents/brokers who arrange sales without taking ownership (425120).[2]

3. Size (this level's rollup figures)

Because 42349 equals its one child, these are also 423490's numbers. All figures are for the merchant-wholesale layer itself (the distributors), not the whole end-market for these products.

Those figures imply roughly $15 million in sales per firm and about 19 employees per location — modest by wholesale standards, consistent with many small distributors around a few giants. Average annual pay works out to roughly $101,000 per worker, reflecting a technically skilled sales-and-logistics workforce rather than a low-wage one.[3][4]

Concentration. The top four firms account for 37.5% of revenue, the top eight for 47.4%, the top 20 for 57.8%, and the top 50 for 69.2%; the Herfindahl-Hirschman Index (a standard antitrust concentration measure) is just 517, which U.S. antitrust agencies treat as "unconcentrated."[3] That low reading is misleading on its own, because it averages across genuinely separate niches (lab, veterinary, surveying, school, religious) that don't compete with one another. Within the lab-supply niche specifically, concentration is far higher — effectively a duopoly (see §8). A second measurement wrinkle: NAICS is assigned at the establishment level, so mapping diversified companies' consolidated revenues onto this code is inherently imprecise.

Where the merchandise actually flows. The code's name suggests an even mix of niches; the Census gross-margin detail does not. Sales are partially suppressed to protect confidential company information, but the available detail shows that scientific, laboratory, veterinary, surveying and related professional distribution — not church and school goods — accounts for most merchandise flow.[6] For an investor, that means the level's economics are essentially the economics of lab and veterinary distribution, with the other niches as rounding error.

Undercount / scope caveats. Wholesale receipts capture only product that flows through distributors; manufacturers that sell scientific instruments direct to large customers (a growing share) bypass this layer, so $35.2 billion understates the true end-market for these goods. Independent market-research estimates put the U.S. laboratory-supplies market alone near $13.8 billion in 2024 and the U.S. lab-equipment market around $10 billion — separate slices of a larger flow that this NAICS only partly intermediates.[7]

4. Investable universe (where value concentrates)

Because this level is its one child, value concentrates exactly where it does in 423490: in the scientific/laboratory slice, and overwhelmingly in the two national broad-line lab distributors. Genuine public pure-plays are scarce; most sizeable platforms are private-equity-owned. In brief (tickers reserved for this section):

• Avantor (AVTR, NYSE) — owns VWR, a leading broad-line lab distributor; the main listed pure-play. $6.552 billion revenue in FY2025, of which the Laboratory Solutions segment was $4.4 billion; the rest is bioprocessing materials.[8][9]
• Thermo Fisher Scientific (TMO, NYSE) — owns Fisher Scientific, the largest U.S. broad-line lab channel, but embedded in a diversified life-sciences maker and services firm. Its Laboratory Products & Biopharma Services segment reported $23.984 billion of revenue and $3.35 billion of segment income in 2025 — though that segment also contains contract pharma manufacturing and clinical-research services, so it is far broader than distribution.[10]
• Private platforms — Covetrus (animal health, taken private for ~$4 billion in 2022), Patterson Companies (~$4.1 billion, taken private in April 2025; its Animal Health segment ran $4.067 billion of fiscal-2024 sales at roughly a 3.4% operating margin), and School Specialty (recapitalized through Chapter 11 in 2020); plus thousands of small regional/niche independents, mostly well under the 150-employee SBA threshold.[5][11][13][14][15]

Adjacent but not distributors: the equipment makers (Danaher, Mettler-Toledo, Waters, Bruker in lab; Trimble, Hexagon, Topcon in geospatial) sell through this channel but are a different kind of bet. See 423490 §4 for the full table and scale figures.

5. How the money works

Merchant wholesalers earn the spread between what they pay manufacturers and what they charge end users, minus the cost of carrying inventory, picking/packing/shipping, and supporting customers. Gross margins are thin-to-moderate; the model is a volume-and-breadth game — carry tens of thousands of SKUs (stock-keeping units) across many suppliers so a lab can do one-stop procurement, then fulfill reliably at low unit cost. Avantor's VWR channel illustrates the scale required: millions of SKUs, more than 5,000 suppliers connected to its private-label program, and roughly 2,000 associates in customer-facing value-added services.[9]

Key profit levers: recurring consumables (reagents, glassware, tips, filters) that reorder continuously versus episodic capital equipment — the razor/razorblade dynamic, at its extreme in Patterson's Animal Health segment, where consumables were 95% of fiscal-2024 segment sales and equipment just 3%[13]; private-label penetration; vendor rebates and "core vendor" fees; e-procurement lock-in (punch-out catalogs wired into customer purchasing systems — roughly 45% of Avantor's 2025 sales came from customers of at least 15 years' standing)[9]; and value-added services. Because margins are slim, the business lives on inventory turns and receivables management.

The margin structure is more modest than the parent page previously implied. At Avantor, consolidated gross margin was 32.7% in 2025 (down from 33.6% in 2024), and Laboratory Solutions produced $510 million of adjusted operating income on $4.4 billion of sales — roughly an 11.6% adjusted operating margin, against about 26% in its bioprocessing-materials segment.[8][9] Pure distribution is a scale-dependent, modest-margin business; the richest profits in this space sit closer to manufacturing than to resale. Full mechanics in 423490 §5.

6. Demand drivers

Demand tracks how much research, testing, building, teaching, and animal care is happening, which varies by niche. For lab and scientific goods the swing factor is research spending: U.S. R&D performance totaled $937 billion in 2023, with an estimate of $993 billion for 2024, and higher-education R&D expenditures reached $108.7 billion in fiscal 2023, of which HHS (including the National Institutes of Health) supplied $33.1 billion.[16][17] That federal dependence cuts both ways — 2025 brought sharp cuts, with more than 3,800 NIH grants terminated or frozen and a proposed ~40% NIH budget reduction, a direct near-term headwind.[18] Elsewhere: biopharma/bioprocessing manufacturing growth and onshoring; customer capital-expenditure cycles for instruments; pet ownership and per-pet spending for veterinary (the American Pet Products Association reports $158 billion of U.S. pet spending in 2024, including $41.0 billion of veterinary care and product sales)[19]; construction and infrastructure for surveying/geospatial; and school enrollment and budgets for classroom supplies (with religious and drafting/print niches in secular decline). Cutting across all of it, procurement consolidation and digitization favor scale distributors while handing customers more bargaining power. See 423490 §6.

7. Regulation

Compared with the excluded medical/dental wholesalers (NAICS 423450), this code is comparatively light-touch because it carves out FDA-regulated medical devices. But distributors still sit inside several regimes: hazardous-materials transport (Department of Transportation / PHMSA 49 CFR; IATA/IMDG for air and sea) for shipping chemicals, reagents, and dry ice; Drug Enforcement Administration (DEA) registration for scheduled reagents and List I/II precursor chemicals; export controls and sanctions (dual-use instruments under the Export Administration Regulations (EAR), administered by the Commerce Department's Bureau of Industry and Security (BIS); some items under ITAR); EPA Toxic Substances Control Act and OSHA hazard-communication rules (Safety Data Sheets) for catalog chemicals; FDA rules on prescription animal drugs and medicated feeds for the veterinary slice, including Veterinary Feed Directive notification and two-year record-keeping obligations on distributors; and government-procurement gatekeepers (GSA schedules, Trade Agreements Act country-of-origin compliance) because so much revenue comes from public universities and federal/state labs. The net burden is moderate — and itself a barrier to entry for small players. Detail in 423490 §7.

8. Consolidation

The structure is a barbell: two national broad-line giants at the top of the lab niche and a long tail of specialists below. Fisher Scientific (Thermo Fisher) and VWR (Avantor) dominate U.S. broad-line laboratory distribution — Avantor bought VWR for $6.4 billion in 2017 — and their scale, catalog breadth, logistics, and institutional contracts are the real moats.[20][21] Elsewhere a private-equity wave has rolled up the middle tier: veterinary distribution consolidated into Covetrus (formed in 2019 from Henry Schein's animal-health unit and Vets First Choice, then taken private by CD&R and TPG in 2022), Patterson Companies went private in 2025, and School Specialty was recapitalized through bankruptcy in 2020.[11][13][14][15] That wave is still running: in February 2026 Cencora agreed to combine MWI Animal Health with Covetrus, valuing MWI at $3.5 billion with Cencora contemplated to retain a 34.3% noncontrolling stake — a further tightening of animal-health distribution.[12] Countervailing pressure comes from disintermediation — manufacturers selling direct to large accounts and e-commerce marketplaces (notably Amazon Business) shipping commodity supplies cheaply — plus group purchasing organizations (GPOs) pressing on price.[20] See 423490 §8.

9. Risks

The main risks are those of 423490: research-funding cyclicality (the 2025 NIH/NSF cuts are a live headwind for the academic slice, and Avantor warns explicitly that funding cuts or delays cause labs to defer purchases[9][18]); customer capital-expenditure sensitivity (instruments fall first in downturns); margin compression from disintermediation, Amazon Business, and GPO pricing[20]; dependence on manufacturer rebates and allocation; tariff and supply-chain exposure on imported equipment, including sole-sourced raw materials and sourcing changes forced by tariffs[9]; thin-margin working-capital and freight intensity; compliance exposure (hazmat, export-control, sanctions); cybersecurity — customers wire procurement systems straight into distributor platforms, so an outage stops order entry, inventory visibility, invoicing, and regulated-product traceability at once; and currency risk plus secular decline in some niches (religious, drafting/print). Full discussion in 423490 §9.

10. How to invest & outlook

Public routes are narrow: Avantor (AVTR) is the most direct listed bet on the distribution layer, but it is a turnaround (revenue declining, activist involved, a new chief executive since August 2025, and a ~$400 million "Revival" cost program), not a steady compounder; Thermo Fisher (TMO) offers distribution exposure via Fisher Scientific inside a diversified, higher-quality franchise.[8][10] Equipment makers and life-science-tools funds give exposure to the products, not the distribution spread. Private routes dominate the middle: the sector is a favorite for private-equity buy-and-build (Covetrus, Patterson, School Specialty are PE-owned), with a steady supply of small regional distributors to roll up and private credit to these leveraged platforms.

Outlook (forward-looking judgment, not reported fact). Near term, research-funding cuts and soft biopharma capital spending are headwinds through 2026, offset by biopharma-manufacturing onshoring, infrastructure spending (geospatial), and rising pet-health spending. Structurally, e-commerce and manufacturer-direct selling should keep pressure on distributor margins, and the durable winners are likely the scale players leaning on private label, services, and e-procurement lock-in. Consolidation and private-equity ownership of the middle tier look set to continue. For the full argument and company-by-company detail, see the child primer, 423490 §10.

---

Sources

1. U.S. Census Bureau. "2022 NAICS Definition — 423490 Other Professional Equipment and Supplies Merchant Wholesalers" (national industry under NAICS industry 42349). census.gov/naics. https://www.census.gov/naics/?input=423490&year=2022
2. NAICS Association. "NAICS Code 423490 — Description, Examples, and Cross-References (2022)." naics.com, 2024. https://www.naics.com/naics-code-description/?v=2022&code=423490
3. U.S. Census Bureau. "2022 Economic Census — Concentration by Largest Firms (NAICS 42349/423490): receipts $35.2B; 2,282 firms; CR4 37.5%, CR8 47.4%, CR20 57.8%, CR50 69.2%; HHI 517.3." 2025. https://data.census.gov/
4. U.S. Census Bureau. "County Business Patterns 2023 (NAICS 42349): 2,392 establishments; 44,956 employees; $4.53B annual payroll; $1.21B Q1 payroll." 2025. https://www.census.gov/programs-surveys/cbp.html
5. U.S. Small Business Administration. "Table of Small Business Size Standards (NAICS 423490 = 150 employees)." 2023. https://www.sba.gov/document/support-table-size-standards
6. U.S. Census Bureau. "2022 Economic Census — Gross Margin Table (NAICS 423490): purchases, inventory, COGS, operating expenses; sales suppressed." 2025. https://data.census.gov/table/ECNGRMARGPROF2022.EC2242GRMARGPROF
7. Precedence Research / Grand View Research. "U.S. Laboratory Supplies and Laboratory Equipment Market Size, 2024." 2025. https://www.precedenceresearch.com/laboratory-supplies-market
8. Avantor, Inc. "Full Year 2025 Results and Leadership Transition: revenue $6.552B; CEO transition August 2025; ~$400M transformation ('Revival') program." Investor Relations, 2026. https://ir.avantorsciences.com/
9. Avantor, Inc. "2025 Form 10-K: Laboratory Solutions $4.4B, $510.4M adj. operating income; gross margin 32.7%; supplier and customer relationships; risk factors." SEC, 2026. https://www.sec.gov/Archives/edgar/data/1722482/000162828026007118/avtr-20251231.htm
10. Thermo Fisher Scientific Inc. "2025 Form 10-K: Laboratory Products & Biopharma Services segment $23.984B revenue, $3.35B segment income." SEC, 2026. https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm
11. Covetrus. "Covetrus to Be Acquired by Clayton, Dubilier & Rice and TPG at an Enterprise Valuation of Approximately $4 Billion." 2022. https://covetrus.com/newsroom/covetrus-to-be-acquired-by-clayton-dubilier-rice-and-tpg-at-an-enterprise-valuation-of-approximately-4-billion/
12. Cencora Inc. "SEC Filing: Cencora to combine MWI Animal Health with Covetrus; MWI valued at $3.5B; 34.3% noncontrolling stake." February 2026. https://www.sec.gov/Archives/edgar/data/1140859/000110465926016785/tm266695d1_ex99-1.htm
13. Patterson Companies. "2024 Form 10-K: Animal Health segment $4.067B sales, $139.1M operating income; 95% consumables mix." SEC, 2024. https://www.sec.gov/Archives/edgar/data/891024/000089102424000008/pdco-20240427.htm
14. Businesswire / Latham & Watkins. "Patient Square Capital completes ~$4.1B acquisition of Patterson Companies; delisted from NASDAQ, April 2025." 2025. https://www.businesswire.com/news/home/20250422266470/en/
15. Office Products International / PR Newswire. "School Specialty Chapter 11 recapitalization (2020) and EPS literacy/math divestiture to Excolere (2023)." 2023. https://www.prnewswire.com/news-releases/school-specialty-announces-the-sale-of-supplemental-literacy-and-math-business-301769101.html
16. National Center for Science and Engineering Statistics. "U.S. R&D Performance: $937B (2023), $993B estimate (2024)." NSF, 2025. https://ncses.nsf.gov/pubs/nsf26314
17. National Science Foundation. "Higher Education R&D Survey: $108.681B FY2023; HHS/NIH $33.1B of university R&D funding." 2025. https://ncses.nsf.gov/pubs/nsf25313/table/3
18. Science (AAAS) / STAT. "NIH and NSF Funding Cuts, 2025: >3,800 grants terminated or frozen; proposed ~40% NIH budget reduction." 2025–2026. https://www.science.org/content/article/odds-winning-nih-grants-plummet-new-funding-policy-and-spending-delays-bite
19. American Pet Products Association. "Industry Trends and Stats: $158B U.S. pet spending 2024, including $41.0B veterinary care." 2025. https://americanpetproducts.org/industry-trends-and-stats
20. LabPro Services / In Practise. "The Structure of U.S. Lab-Supply Distribution: broad-line distributors, vendor fees, private label, Amazon Business, and the Avantor–VWR ($6.4B, 2017) consolidation." 2024–2026. https://www.labproservices.com/Blog/the-future-of-lab-supplies-distribution/
21. Chemical & Engineering News. "Avantor acquires VWR for $6.4 billion (2017)." https://pubs.acs.org/doi/10.1021/cen-09520-notw12